Arovella Newsletter December 2024
Welcome to this edition of the Arovella newsletter as we bring the year 2024 to a close. It has been a productive year for the company, as we continued to make advances taking ALA-101 toward phase 1 clinical trials. This included working towards completing the activities required for filing our IND, GMP manufacturing of ALA-101 for clinic and completion of the IND-enabling studies required for submission of our IND. We made progress for clinical trial readiness, garnering feedback from key opinion leaders (KOLs) and potential sites for our phase 1 clinical trial design.
Highlights:
Established Clinical Advisory Board
Continued advancing ALA-101 towards a first-in-human clinical trial
Offered US$150,000 funding as part of the G-Rex® Grant Program
Received positive analyst coverage from MST Access
Attended Cell Therapy on the Mesa in Phoenix, AZ
